Effects of Sibutramine Plus Orlistat in Obese Women Following 1 Year of Treatment by Sibutramine Alone: A Placebo‐Controlled Trial
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Objective: This study assessed whether adding orlistat to sibutramine would induce further weight loss in patients who previously had lost weight while taking sibutramine alone. Research Methods and Procedures: Patients were 34 women with a mean age of 44.1 ± 10.4 years, weight of 89.4 ± 13.8 kg, and body mass index (BMI) of 33.9 ± 4.9 kg/m 2 who had lost an average of 11.6 ± 9.2% of initial weight during the prior 1 year of treatment by sibutramine combined with lifestyle modification. Patients were randomly assigned, in double‐blind fashion, to sibutramine plus orlistat or sibutramine plus placebo. In addition to medication, participants were provided five brief lifestyle modification visits during the 16‐week continuation trial. Results: Mean body weight did not change significantly in either treatment condition during the 16 weeks. The addition of orlistat to sibutramine did not induce further weight loss as compared with treatment by sibutramine alone (mean changes = +0.1 ± 4.1 kg vs. +0.5 ± 2.1 kg, respectively). Discussion: These results must be interpreted with caution because of the study's small sample size. The findings, however, suggest that the combination of sibutramine and orlistat is unlikely to have additive effects that will yield mean losses ≥15% of initial weight, as desired by many obese individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632 · cited 1×
“This was the promise of the fenfluramine-phentermine combination until the fenfluramines were removed from the market in 1997 because of their association with valvular heart disease (”
BackgroundSjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947
Foster, G. D., Wadden, T. A., Vogt, R. A., & Brewer, G. (1997) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.65.1.79 · Cited by 447
Self-citationOrlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
Hill, J. O., Hauptman, J., Anderson, J. W., Fujioka, K., O'Neil, P. M., Smith, D. K., Zavoral, J. H., & Aronne, L. J. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.6.1108 · Cited by 287
Anorectic agents lower a body weight set point
Stunkard, A. J. (1982) · Life Sciences · doi:10.1016/0024-3205(82)90445-3 · Cited by 100
Behavioural treatment of the overweight patient
Wadden, T. A., Sarwer, D. B., & Berkowitz, R. I. (1999) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1053/beem.1999.0008 · Cited by 48
Self-citation
Cited by
Avenell, A., Broom, J., Brown, T., Poobalan, A., Aucott, L., Stearns, S., Smith, W., Jung, R., Campbell, M., & Grant, A. (2004) · Health Technology Assessment · doi:10.3310/hta8210 · Cited by 1,041
The Look AHEAD Study: A Description of the Lifestyle Intervention and the Evidence Supporting It
The Look AHEAD Research Group (2006) · Obesity · doi:10.1038/oby.2006.84 · Cited by 873
Meta-Analysis: Pharmacologic Treatment of Obesity
Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L. R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P. G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00012 · Cited by 774
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753
Appropriate Intervention Strategies for Weight Loss and Prevention of Weight Regain for Adults
JAKICIC (CHAIR), J. M., CLARK, K., COLEMAN, E., DONNELLY, J. E., FOREYT, J., MELANSON, E., VOLEK, J., & VOLPE, S. L. (2001) · Medicine & Science in Sports & Exercise · doi:10.1097/00005768-200112000-00026 · Cited by 752
Yanovski, S. Z., & Yanovski, J. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra012586 · Cited by 544
One-year weight losses in the Look AHEAD study: factors associated with success
Wadden, T. A., West, D. S., Neiberg, R. H., Wing, R. R., Ryan, D. H., Johnson, K. C., Foreyt, J. P., Hill, J. O., Trence, D. L., Vitolins, M. Z., et al. (2009) · Obesity · doi:10.1038/oby.2008.637 · Cited by 525
Self-citationPosition of the American Dietetic
Cummings, S., Parham, E. S., & Strain, G. W. (2002) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(02)90255-5 · Cited by 432
Rational Design of a Combination Medication for the Treatment of Obesity
Greenway, F. L., Whitehouse, M. J., Guttadauria, M., Anderson, J. W., Atkinson, R. L., Fujioka, K., Gadde, K. M., Gupta, A. K., O'Neil, P., Schumacher, D., et al. (2009) · Obesity · doi:10.1038/oby.2008.461 · Cited by 345
Drug Treatment of the Overweight Patient
Bray, G. A., & Ryan, D. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.053 · Cited by 115
A systematic review of the clinical effectiveness of orlistat used for the management of obesity
O'Meara, S., Riemsma, R., Shirran, L., Mather, L., & Ter Riet, G. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00125.x · Cited by 103
“obesity reviews 5 , 51–68 istat as an adjunctive agent (38,39), and another two compared orlistat with other anti-obesity preparations (36,37).”
BackgroundMethodInfluentialHow Physician Obesity Specialists Use Drugs to Treat Obesity
Hendricks, E. J., Rothman, R. B., & Greenway, F. L. (2009) · Obesity · doi:10.1038/oby.2009.69 · Cited by 97
“There was no additional weight loss during this 16-week study (10).”
BackgroundBays, H. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.125 · Cited by 66
Atkinson, T. J. (2008) · Obesity Reviews · doi:10.1111/j.1467-789x.2007.00412.x · Cited by 49
“However, a longer term 12-month placebo-controlled trial (98) of sibutramine plus orlistat did not significantly induce more weight loss than sibutramine alone; but the study was limited by its small sample size.”
Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk
Bays, H., Rodbard, H. W., Schorr, A. B., & González-Campoy, J. M. (2007) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-007-0021-6 · Cited by 36
Tronieri, J. S., Wadden, T. A., Walsh, O. A., Berkowitz, R. I., Alamuddin, N., Gruber, K., Leonard, S., & Chao, A. M. (2019) · Metabolism · doi:10.1016/j.metabol.2019.03.005 · Cited by 29
Self-citation
Metadata
- Authors
- Wadden, T. A., Berkowitz, R. I., Womble, L. G., Sarwer, D. B., Arnold, M. E., & Steinberg, C. M.
- Venue
- Obesity Research
- Publisher
- Wiley
- Published
- 2000-09
- Volume
- 8
- Issue
- 6
- Pages
- 431-437
- ISSN
- 1071-7323 (ISSN-L)
- 1550-8528
- OpenAlex
- W1972032386
- Cited by
- 117
- References
- 7
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.